New schizophrenia drug to lead the market by 2016.
Newly approved in the EU, Abilify Maintena is set to become the leading injectable schizophrenia treatment within the next three years, worth $842m by 2021
Independent analyst firm Datamonitor Healthcare has forecast that the long-acting depot therapy Abilify Maintena, which was approved for EU use last month, will become the leading injectable schizophrenia therapy by 2016.
Datamonitor Healthcare also forecasts that the drug will generate annual sales worth up to $842m by 2021 in the US, Japan and five major EU markets*.
Abilify Maintena (Otsuka/Lundbeck) is expected to act as strong competition for other long-acting depot formulas, such as Johnson and Johnson’s Invega Sustenna and Risperdal Consta, due to its favourable tolerability profile.
Natasha Spiller, analyst at Datamonitor Healthcare said: “The key advantage of long-acting formulations over oral therapies is their ability to improve patient compliance, which is an important consideration for long-term maintenance therapy.
“The development of injectable formulations represents one of the final strategies left for companies to drive growth through this mature market. We expect the value of depot formulations to increase from $1.1bn in 2012 to $1.4bn by 2021 in the seven major markets**, despite the fact that we’re forecasting a slight decline in the overall schizophrenia market during the next ten years.”
The predicted decline in the schizophrenia market is due to limited novelty in the development pipeline and generic erosion of key marketed brands, but Datamonitor Healthcare forecasts that the market will be worth $4.1bn by 2021 in the seven major markets**.
Additional forecasts, opinion and research from Datamonitor Healthcare is available at www.datamonitorhealthcare.com
*5 major EU markets = France, Germany, Italy, Spain, UK
** 7 major markets = US, Japan and the 5 major EU markets.
Media Contact: Lucy Giles @ MC2 | 0161 236 1352 | LucyG@mcmc.co.uk
About Datamonitor Healthcare
Datamonitor Healthcare is a world-leading provider of premium business information, delivering research and analysis of all aspects of the healthcare sector.
Notes to editors
Whenever citing an analyst or quote, please remember to use ‘Datamonitor Healthcare’ rather than ‘Datamonitor’.
For descriptive purposes, Datamonitor Healthcare is a “leading research and consulting firm.”
Whenever possible, please hyperlink:
The Datamonitor Healthcare name to www.datamonitorhealthcare.com
Any reports used to the correct URL for that listing on our Report Store.
Please note that all supplied to the media, is owned exclusively by Datamonitor Healthcare, is governed by our terms and conditions, and therefore must be referenced.
Posted in Uncategorized.